Skip to content

A single group clinical study to assess THE COMBINED EFFECTIVENESS of VRIKKASHEKHARA KASHAYA and KAISHORA GUGGULU in CHRONIC KIDNEY DISEASE (CKD)

A single arm clinical trail to assess the COMBINED EFFECTIVENESS OF VRIKKASHEKHARA KASHAYA AND KAISHORA GUGGULU in the management of CHRONIC KIDNEY DISEASE (CKD)

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/07/020232
Enrollment
30
Registered
2019-07-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)

Interventions

Intervention1: Kaishora guggulu 1 tab thrice a day. Vrikkashekara kashaya 30ml thrice a day.: Kaishore guggulu 500mg along with Vrikkashekhara kashaya(Anubhuta yoga) which consists of Mutrala, Raktash

Sponsors

Ayurveda Mahavidyalaya And Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects with classical symptoms of CHRONIC KIDNEY DISEASE having the clinical features like Oedema Pruritis Generalized weakness Nausea etc. GFR (30-100ml/min per 1.73m2) Albuminuria Serum creatinine (0.5-6mg/dl) Blood urea (10-60mg/dl) Mild Hypertension. Subjects of both the genders. Subjects belonging to age group between 20- 60 years of age.

Exclusion criteria

Exclusion criteria: Subjects who donâ??t fulfill the inclusion criteria will be excluded from the study. CKD subjects of stage-4 & stage-5 are excluded. Subjects who are on dialysis therapy. Subjects suffering from Hepatitis/HIV/VDRL will be excluded. Uncontrolled DM. Hypertension above 180/110mm of Hg. Pregnant & Lactating women.

Design outcomes

Primary

MeasureTime frame
Oedema. Pruritis. Nausea. Generalized weakness. Pallor Timepoint: At the end of the 60 days clinical trial.

Secondary

MeasureTime frame
Serum creatinine. Hb%. Urine for Albumin. Blood urea. GFR. Blood Pressure. Timepoint: At the end of 60 days of clinical trial.

Countries

India

Contacts

Public ContactDr Prashanth A S

Ayurveda Mahavidyalaya And Hospital

rajshekharshettar@gmail.com7204286255

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026